Compare Kaltura Inc (KLTR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Tango Therapeutics Inc. — how do they compare? Kaltura Inc trades at $1.38 (market cap $212.05M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 17.7× Kaltura Inc's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Tango Therapeutics Inc. for 0 Days on average.
| KLTR | TNGX | |
|---|---|---|
Market Cap | $212.05M | $3.75B |
Volume | 264,699 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $1.89 | $32.90 |
52-Week Low | $1.08 | $7.50 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $224.26M | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLTR trades at $1.37, down 2.14% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported revenue of $180.85M in 2025, with a net loss of $12.07M, though losses have narrowed significantly from prior years. Recent news highlights include Gartner naming Kaltura a leader in AI for video platform services and a strategic partnership with Verimatrix for security.
The outlook remains speculative; while AI-driven growth and improving margins present upside potential, persistent losses, high valuation ratios, and negative cash flow pose substantial risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, but the stock's high volatility and weak profitability metrics warrant careful consideration.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
